Lymphatica Medtech
Lymphatica Medtech SA, a clinical-stage company based in Lausanne, Switzerland, specialised in innovative treatments for lymphedema, has raised 17.9 million EUR in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide.
A 'first of its kind' device according to the company, LymphoDrain is easy to implant subcutaneously through a minimally invasive technique and it’s intended to provide unprecedent benefits to patients by locally and actively replacing the lymphatic vessels draining function.
The funding round was co-led by Panakès Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also participated in this round.
To support its growth, Lymphatica has also opened a subsidiary in Italy to expand its R&D efforts and manage manufacturing and clinical operations. Lymphatica is further strengthened by the appointment of Dan Rose as the new Chairman of the Board; Rose brings leadership experience from LimFlow (acquired by Inari Medical), Direct Flow Medical, Sequana Medical, and Medtronic. Additionally, Alessio Beverina, Managing Partner at Panakès, and Lukas Guenther, Chief Investment Officer at TechWald Next, have joined the Board of Directors, alongside existing independent board member Nanci Govinder.
“We are thrilled to have closed our Series B financing, which will enable us to advance the clinical development of our groundbreaking technology for lymphedema patients,” said Dr. Marco Pisano, CEO and co-founder of Lymphatica Medtech. “With the support of our investors and new board members, we are one step closer to delivering a transformative solution that will significantly improve the lives of those suffering from lymphedema.”
Valentina Triacca, COO and co-founder of Lymphatica Medtech, added: “Millions of people live with chronic lymphedema, and current treatment options fall short of providing effective relief. This investment allows us to continue advancing our LymphoDrain device, which has already shown promising results in a pilot feasibility study.”
“Lymphatica has made impressive progress in developing a compelling technology that has the potential to transform care and improve the lives of the many patients suffering from Lymphedema today” said Dan Rose. “It is a privilege to join the Board as Chairman and to support the efforts of this great team”.
Alessio Beverina, Managing Partner at Panakès said: “Lymphatica is addressing a massive unmet medical need, with over 10 million people affected by lymphedema. This technology has the potential to transform the lives of those patients.”
Lukas Guenther, CIO of TechWald added: "With its technology, Lymphatica is well-positioned to bring true sustainable clinical innovation in the treatment of lymphedema, greatly benefiting patients, physicians, and healthcare systems in various countries around the world."
